Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
SLDB Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SLDB Stock 12 Month Forecast
Average Price Target
$15.60
▲(192.68% Upside)
| Highest Price Target$20.00 | Average Price Target$15.60 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
09/23/25
Solid Biosciences: Strategic Collaborations and Regulatory Progress Drive Buy RatingWe view the licensing agreement favorably as it validates the differentiated safety profile and muscle-targeted tropism of AAV-SLB101. The addition of Solid’s growing network of collaborators underscores the broad applicability and industry confidence in the AAV-SLB101 capsid. We also view Solid’s collaboration with Kinea and others as a positive for the company because they can accelerate data generation across more indications, deepening insights into the capsid’s performance and reinforcing Solid’s expertise. Regarding its internal pipeline, we believe the company’s interactions with regulators regarding SGT-003 will be a near-term catalyst for the stock, given the recent volatility in FDA leadership and regulatory philosophy for rare diseases.
Cantor Fitzgerald
$16
Buy
200.19%
Upside
Reiterated
09/22/25
H.C. Wainwright
$20
Buy
275.23%
Upside
Reiterated
09/17/25
Citizens JMP
$15
Buy
181.43%
Upside
Reiterated
09/12/25
Barclays
$10
Buy
87.62%
Upside
Reiterated
09/10/25
Citi
$14→$16
Buy
200.19%
Upside
Reiterated
08/14/25
Leerink Partners
$20
Buy
275.23%
Upside
Reiterated
08/13/25
Solid Biosciences Gains Momentum with Promising DMD Program and Strategic ExpansionWe caught up with management and while they see the clear unmet need for non-ambulatory DMD patients, they are planning to build up a substantial safety database before moving into this population. They also made it clear that they are treating boys up to <12, so they are treating sicker and older patients up to 40 kg, but this population also gives them a better shot at demonstrating a clear benefit (along with other strategic differences, including a focus on time-to-rise and stride velocity vs. NSAA and an 18-month endpoint).
Truist Financial
―
Buy
―
Reiterated
08/13/25
Chardan Capital
$15
Buy
181.43%
Upside
Reiterated
08/13/25
Wedbush
$17→$14
Buy
162.66%
Upside
Reiterated
08/13/25
Piper Sandler
$17
Buy
218.95%
Upside
Reiterated
08/13/25
J.P. Morgan
$15→$13
Buy
143.90%
Upside
Reiterated
08/13/25
Jefferies
$16→$15
Buy
181.43%
Upside
Reiterated
05/16/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
09/23/25
Solid Biosciences: Strategic Collaborations and Regulatory Progress Drive Buy RatingWe view the licensing agreement favorably as it validates the differentiated safety profile and muscle-targeted tropism of AAV-SLB101. The addition of Solid’s growing network of collaborators underscores the broad applicability and industry confidence in the AAV-SLB101 capsid. We also view Solid’s collaboration with Kinea and others as a positive for the company because they can accelerate data generation across more indications, deepening insights into the capsid’s performance and reinforcing Solid’s expertise. Regarding its internal pipeline, we believe the company’s interactions with regulators regarding SGT-003 will be a near-term catalyst for the stock, given the recent volatility in FDA leadership and regulatory philosophy for rare diseases.
Cantor Fitzgerald
$16
Buy
200.19%
Upside
Reiterated
09/22/25
H.C. Wainwright
$20
Buy
275.23%
Upside
Reiterated
09/17/25
Citizens JMP
$15
Buy
181.43%
Upside
Reiterated
09/12/25
Barclays
$10
Buy
87.62%
Upside
Reiterated
09/10/25
Citi
$14→$16
Buy
200.19%
Upside
Reiterated
08/14/25
Leerink Partners
$20
Buy
275.23%
Upside
Reiterated
08/13/25
Solid Biosciences Gains Momentum with Promising DMD Program and Strategic ExpansionWe caught up with management and while they see the clear unmet need for non-ambulatory DMD patients, they are planning to build up a substantial safety database before moving into this population. They also made it clear that they are treating boys up to <12, so they are treating sicker and older patients up to 40 kg, but this population also gives them a better shot at demonstrating a clear benefit (along with other strategic differences, including a focus on time-to-rise and stride velocity vs. NSAA and an 18-month endpoint).
Truist Financial
―
Buy
―
Reiterated
08/13/25
Chardan Capital
$15
Buy
181.43%
Upside
Reiterated
08/13/25
Wedbush
$17→$14
Buy
162.66%
Upside
Reiterated
08/13/25
Piper Sandler
$17
Buy
218.95%
Upside
Reiterated
08/13/25
J.P. Morgan
$15→$13
Buy
143.90%
Upside
Reiterated
08/13/25
Jefferies
$16→$15
Buy
181.43%
Upside
Reiterated
05/16/25
Best Analysts Covering Solid Biosciences
1 Month
xxx
Success Rate
5/12 ratings generated profit
Average Return
+3.44%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of +3.44% per trade.
3 Months
xxx
Success Rate
5/13 ratings generated profit
Average Return
+7.31%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of +7.31% per trade.
1 Year
Success Rate
4/8 ratings generated profit
Average Return
+20.25%
reiterated a buy rating 13 days ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.25% per trade.
2 Years
xxx
Success Rate
4/8 ratings generated profit
Average Return
+20.25%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +20.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SLDB Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
17
14
19
19
18
Buy
6
4
7
7
7
Hold
1
0
0
0
0
Sell
3
1
0
0
0
Strong Sell
0
0
0
0
0
total
27
19
26
26
25
Each month's total comprises the sum of three months' worth of ratings.
SLDB Financial Forecast
SLDB Stock Forecast FAQ
What is SLDB’s average 12-month price target, according to analysts?
Based on analyst ratings, Solid Biosciences’s 12-month average price target is 15.60.
What is SLDB’s upside potential, based on the analysts’ average price target?
Solid Biosciences has 192.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SLDB a Buy, Sell or Hold?
Solid Biosciences has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Solid Biosciences’s price target?
The average price target for Solid Biosciences is 15.60. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 192.68% Increase from the current price of $5.33.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 192.68% Increase from the current price of $5.33.
What do analysts say about Solid Biosciences?
Solid Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of SLDB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.